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Abstract: Excessive sleepiness (ES) is a major but underestimated public health concern 
associated with significant impairments in alertness/wakefulness and significant morbidity. 
The term ES has been used in the sleep medicine literature for years, but due to its nonspecific 
symptoms (ie tiredness or fatigue), it frequently goes unrecognized or is misdiagnosed in 
primary care. In some cases ES arises due to poor sleep habits or self-imposed sleep deprivation; 
however, ES is also a key component of a number of sleep/wake disorders and multiple medical 
and psychiatric disorders. Identification and treatment of ES is critical to improve the quality 
of life and well-being of patients and for the safety of the wider community. The inability of 
patients to recognize the nature, extent, and symptomatic profile of sleep/wake disorders requires 
vigilance on the part of healthcare professionals. Interventions to address ES and its associated 
impairments, treatment of the underlying sleep/wake disorder, and follow-up are a priority 
given the potential for serious consequences if left untreated. Wakefulness-promoting agents 
are available that treat ES associated with sleep/wake disorders. This review examines current 
approaches for managing this debilitating and potentially life-threatening condition, focusing 
on the place of armodafinil as a wakefulness-promoting agent.
Keywords: excessive sleepiness, wakefulness, armodafinil, obstructive sleep apnea, narcolepsy, 
shift-work disorder
Introduction
Excessive sleepiness (ES) is a chronic inability to maintain alertness during waking 
episodes.1 This impairment in wakefulness interferes with the activities of daily 
living and can increase the risk for sleep-related accidents at work, at home, and on 
the road.2–5 Moreover, ES can cause significant impairment to an individual’s work 
performance, overall well-being, clinical condition, psychological health and function, 
executive function, and social relationships.2,6–9 ES is associated with many medical and 
psychiatric disorders; this review will focus on the sleep/wake disorders obstructive 
sleep apnea (OSA), narcolepsy, and shift-work disorder (SWD).10–12
Sleepiness is infrequently voiced as a presenting symptom for patients with ES, 
who instead report that they are experiencing tiredness, fatigue, or a lack of energy. 
Identifying and managing patients with ES requires a comprehensive approach to 
address any underlying condition and improve sleep practices. If ES arises from 
chronic self-imposed sleep restriction, efforts to improve sleep habits, such as increas-
ing time in bed, may be sufficient. However when ES arises from an underlying 
disorder, interventions are typically required to address both the disorder as well as 
the ES. Wakefulness-promoting agents are proving particularly useful in addressing Neuropsychiatric Disease and Treatment 2010:6 418
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ES in the context of sleep/wake disorders. The introduction 
of armodafinil (Nuvigil®; Cephalon Inc., Frazer, PA), the 
R-enantiomer of the racemic wakefulness-promoting agent 
modafinil,13 has expanded the pharmacologic options avail-
able for the management of ES. This agent is approved for 
the treatment of ES associated with OSA (as adjunctive 
therapy), SWD, and narcolepsy.
This review will explore practical ways in which the recog-
nition of ES can be simplified in clinical practice and current 
approaches to managing this important symptom, focusing on 
the appropriate role of armodafinil in these patients.
Recognizing ES in clinical practice
initial presentation
Vigilance for sleep/wake disorders and ES is necessary as 
clinical presentation can often be confounded by nonde-
script complaints such as tiredness, fatigue, lack of energy, 
apathy, lethargy, poor memory, and poor concentration. 
Patients presenting with ES may not recognize their daytime 
impairment, as their primary complaint may be disturbed 
sleep. For example, many patients with ES, including those 
with OSA, SWD, or narcolepsy, report disturbed sleep, and 
in one study, approximately half of patients diagnosed with 
OSA in a sleep center initially presented with the complaint 
of insomnia.14
Patients presenting with symptoms or risk factors for 
disorders such as OSA, SWD, or narcolepsy often fail to 
recognize their ES or fail to relate cognitive impairments, such 
as an inability to focus or concentrate and memory problems, 
to ES and thus may not volunteer information about sleepiness 
unless specifically asked. A useful approach to differentiating 
ES from a generalized complaint such as fatigue is to ask 
patients if the presenting symptom (ie, “fatigue”) improves 
in sedentary situations. Most patients with ES will report 
an exacerbation of their complaint in soporific conditions, 
whereas patients with mental-, muscle-, or depression-related 
fatigue typically report an improvement during inactivity.
Comorbid conditions
The nonspecific nature of the complaints in patients with 
ES, such as tiredness and fatigue, may lead to a diagnosis 
of depression. This is of particular concern as it may result 
in the inappropriate prescription of antidepressant therapy 
and may lead to a delay in the recognition and treatment of 
ES. Moreover, while depression and sleep/wake disorders 
such as OSA can and frequently do coexist, it is important to 
follow up and screen such patients for the ongoing presence 
of ES. Hypertension, diabetes, and cardiovascular disease 
have a high comorbidity with OSA and associated ES.15 
Consideration of underlying sleep/wake disorders and ES in 
patients presenting with such comorbidities or generalized 
psychiatric complaints suggestive of depression is critical 
in ensuring prompt and appropriate intervention. Table 1 
presents a clinical checklist for the initial identification and 
assessment of ES.
Assessment of ES
The Epworth Sleepiness Scale (ESS) is a useful screening tool 
for identifying ES (Table 2).16 The ESS is a self-administered 
questionnaire that is used worldwide to quantify ES at 
baseline and to monitor ES at follow-up in patients with a 
variety of sleep complaints including OSA and narcolepsy.17,18 
Respondents are asked to determine their likelihood of 
dozing in eight sedentary situations (including sitting and 
reading, watching TV , and in a car while stopped for a few 
minutes in traffic) on a 4-point scale (0 = never, 1 = slight, 
2 = moderate, 3 = high). The total score ranges from 0 to 24, 
and a score 10 indicates an abnormal level of sleepiness. 
Objective laboratory assessments, such as the Multiple Sleep 
Latency Test (MSLT) and the Maintenance of Wakefulness Test 
(MWT), are useful in ruling out specific intrinsic sleep/wake 
disorders such as narcolepsy and in providing an objective 
assessment of sleepiness. While these laboratory measures 
are useful objective assays of sleepiness, the ESS has some 
important advantages in general clinical settings outside the 
sleep disorders center. First, it is easily administered. Second, 
the ESS is extremely valuable as a screening tool to identify 
and quantify sleepiness in at-risk patients. Third, the ESS 
can be used for patient follow-up and management as it is a 
useful indicator of treatment response.17,19
Managing patients with ES
Treatment of ES
The initial steps in treating a patient with ES should be 
to identify and, if possible, address any underlying medical, 
psychiatric, or sleep/wake disorder that contributes to 
their ES and to ensure that the patient is taught good sleep 
hygiene practices. In narcolepsy, ES arises from an intrinsic 
dysfunction in sleep regulation and medication is required 
to enhance wakefulness. For a significant proportion of 
patients with sleep/wake disorders amenable to medical, 
mechanical, or other interventions, ES will persist even with 
appropriate and effective treatment for the underlying disorder. 
Continuous positive airway pressure (CPAP) therapy is the 
gold standard treatment for OSA and ensures that the upper 
airway remains open during sleep by acting as a pneumatic Neuropsychiatric Disease and Treatment 2010:6 419
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splint. However, despite treatment with CPAP therapy, 34% of 
patients with OSA have ongoing subjective sleepiness as 
measured by the ESS, and 65% of patients with OSA have 
persistent objective ES as measured by the MSLT.20 The first 
goal of therapy for OSA is to ensure CPAP compliance, but 
adjunctive pharmacotherapy specifically aimed at improving 
wakefulness may be of benefit to improve the ongoing 
sleepiness that may persist despite CPAP therapy.
Stimulants and wakefulness-promoting 
medications
Stimulants, such as methylphenidate and dextroamphetamine, 
are approved for use in combatting ES in patients with 
narcolepsy but they have an associated potential for abuse 
and adverse cardiovascular and central nervous system (CNS) 
effects.21 Sodium oxybate is approved for the treatment of 
ES and cataplexy in patients with narcolepsy.
The wakefulness-promoting agent modafinil has been 
available since 1999 and offers an alternative to traditional 
stimulants for the treatment of ES. Most recently, the 
R-enantiomer of modafinil – armodafinil – has been approved 
for the treatment of ES associated with SWD, narcolepsy, and 
as an adjunctive therapy for persistent ES in patients being 
treated for OSA. The remainder of this review will focus on 
the role of armodafinil in the management of ES in these 
approved indications.
Armodafinil
Armodafinil (2-[(R)-(diphenylmethyl)sulfinyl]acetamide) is 
an oral wakefulness-promoting agent13 (Figure 1). Plasma 
concentrations of the R-enantiomer remain elevated for a 
prolonged period of time relative to the S-enantiomer (10 to 
14 hours compared with 3 to 4 hours).22–24 To date there have 
been no adequate head to head studies of armodafinil versus 
modafinil in any of its approved indications.
The Food and Drug Administration-approved dose of 
armodafinil for patients with narcolepsy or ES associated 
with OSA is 150 mg or 250 mg taken as a single dose in the 
morning or 150 mg taken 1 hour before the start of the night 
shift for patients with SWD.25
Pharmacology and mode of action
The precise mechanism by which armodafinil and modafinil 
promote wakefulness is unknown but it is likely to involve 
the selective potentiation of CNS catecholaminergic 
signaling.26 Specifically, modafinil may exert its effect 
Table 1 Identification and initial assessment of ES in the clinic
Recognizing ES in the clinic
Presenting profiles alerting a high degree of suspicion for ES
Diagnosed sleep/wake disorder
Cardiovascular disease, particularly obese patients, with or without an underlying sleep/wake disorder
Generalized somatic symptoms with or without an underlying sleep/wake disorder
Employer referral for ES
High-risk professions, eg, shift workers or professional drivers
Polypharmacy (prescription and/or OTC), particularly with drugs that affect the central nervous system such as antidepressants, neuroleptics, 
beta-blockers, analgesics
Clinical goals
exclude or establish comorbidity with an underlying medical disorder, eg anemia, diabetes, neurodegenerative condition
exclude or establish comorbidity with a psychiatric disorder, particularly mood and anxiety disorders
Identify any underlying sleep/wake disorder if undiagnosed
Identify ES component
Screening and assessment of ES
Screening Assessment
  Direct questioning   epworth sleepiness scale
  Multiple sleep latency test
  Maintenance of wakefulness test
Initial treatment of ES
Address any underlying medical disorder improve sleep hygiene
Address underlying sleep/wake disorder Prescribe wakefulness-promoting agent
Abbreviations: eS, excessive sleepiness; OTC, over the counter.Neuropsychiatric Disease and Treatment 2010:6 420
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by increasing electrical coupling across gap junctions 
between neurons.27 Potentiation of glutaminergic synapses 
on hypocretin/orexin neurons in the lateral hypothalamus28 
together with effects on the GABA and monoaminergic 
systems are thought to mediate the wakefulness-promoting 
effects of modafinil and may also account for the observed 
clinical effect of armodafinil.29,30 In addition, although 
armodafinil is not a direct or indirect dopamine receptor 
agonist, it has been shown to bind to the dopamine trans-
porter and inhibit dopamine reuptake.31,32
Pharmacokinetics of armodafinil
Armodafinil displays linear pharmacokinetics over the 50 mg 
to 400 mg dose range.33 The peak plasma concentration is 
reached ∼2 hours after dosing, and steady state is reached 
within ∼7 days with once-daily dosing, with no gender 
effects.33 Food slows the rate but not the extent of absorption 
of armodafinil.33 Elimination of armodafinil is monophasic 
with a mean elimination half-life of ∼15 hours.33
Armodafinil dose reductions should be considered 
for patients with severe hepatic impairment based on an 
observed reduction in oral clearance and an increase in 
the steady-state concentration of modafinil in this patient 
group.25 Similar reductions should be considered for elderly 
patients in whom elimination may be slowed. Armodafinil 
is metabolized via amide hydrolysis followed by sulfone 
formation via the cytochrome P450 (CYP) 3A4/5 enzymes.25 
Dosage adjustment to sustain clinical effect may be necessary 
if patients are receiving other agents that are also substrates 
for these enzymes, eg, steroidal contraceptives, cyclosporine, 
midazolam, and triazolam.25 Armodafinil has also displayed 
reversible inhibition of CYP2C19, and drugs such as diaz-
epam that are metabolized via this enzyme may display 
prolonged elimination and thus lower doses of these agents 
may be required if coadministered.34
Armodafinil for ES in OSA
OSA is a condition characterized by recurrent complete and 
partial obstruction of the airway, resulting in repeated arousal 
from sleep. OSA is the most common of the sleep-related 
breathing disorders.1 In the USA, 9% of women and 24% of 
S
O
O
NH2
Figure 1 Chemical structure of armodafinil.
Table 2 The epworth Sleepiness Scale16
responses:  0 = would never doze
  1 = slight chance of dozing
  2 = moderate chance of dozing
  3 = high chance of dozing
Situation Chance of dozing (complete using responses above)
Sitting and reading
Watching TV
Sitting inactive in a public place such as a meeting
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking with someone
Sitting quietly after a lunch without alcohol
In a car, while stopped for a few minutes in traffic
Total score  
©1991 by the American Academy of Sleep Medicine. Reproduced with permission of the American Academy of Sleep Medicine.Neuropsychiatric Disease and Treatment 2010:6 421
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men meet minimum diagnostic criteria for OSA (5 obstructive 
events per hour), while at least 2% and 4% of women and men, 
respectively, are thought to have OSA with associated ES and 
resultant daytime impairment.35 Patients with OSA may also 
present initially with the complaint of insomnia.14
The efficacy of armodafinil as a therapy to address ES 
in patients who are receiving treatment for OSA has been 
evaluated in 650 individuals who took part in one of 
two phase III studies (Table 3).36,37 Patients recruited into 
these studies had a diagnosis of OSA and also residual ES 
(ESS score 10 points and a Clinical Global Impression of 
Severity of Illness score 4 points) despite effective regular 
CPAP therapy. The MWT was a primary efficacy endpoint 
and this test was used to assess participants at 09:00, 11:00, 
13:00, 15:00, 17:00, and 19:00 at baseline and every 4 weeks 
during treatment with armodafinil (150 or 250 mg daily) or 
placebo until study completion at 12 weeks. Armodafinil 
significantly improved patients’ mean sleep latency at the 
first four MWT assessments at all visits in each study36,37 
(P  0.001) (Figure 2),39 and a post hoc analysis of pooled 
data from both studies also demonstrated that the beneficial 
effects of armodafinil were sustained late in the waking day, 
with a significant improvement relative to placebo observed 
from the first assessment point at week 4 and at the final visit 
(Figure 2).39 However, differences between armodafinil and 
placebo in terms of MWT assessments at timepoints later 
in the day (15:00, 17:00, and 19:00) did not reach statistical 
significance at the final visit in the individual studies.36,37
Clinical condition measured using the Clinical Global 
Impression of Change (CGI-C) was a second primary 
endpoint in both of the studies that evaluated armodafinil 
in patients with ES associated with OSA. In the study 
conducted by Roth and colleagues,36 a significantly greater 
proportion of armodafinil-treated patients experienced at 
least minimal improvement on the CGI-C at all time points 
(P  0.001) compared with patients receiving placebo. The 
proportion of patients in the armodafinil group with at least 
minimal improvement on the CGI-C was also significantly 
higher versus the placebo group at the final visit in the study 
conducted by Hirshkowitz and colleagues (71% vs 53%, 
respectively; P = 0.0069).37
Patients in these studies also completed the 9-item Brief 
Fatigue Inventory. Patients treated with armodafinil 150 or 
250 mg experienced significant reductions in fatigue (–1.2 and 
–1.3 points, respectively) compared with those who received 
placebo (–0.6 points; P  0.01 for both doses vs placebo) 
(Table 3).38 Cognitive performance was assessed with a 
battery of tests aimed at evaluating aspects of memory and 
attention. Both studies individually and the pooled analysis 
of data confirmed that armodafinil significantly improved the 
quality of secondary memory (the ability to store and retrieve 
information) compared with placebo (P  0.05) (Table 3).39 
Armodafinil also significantly improved the overall ESS 
score as well as patients’ ability to participate in activities of 
daily living from the first assessment at 4 weeks (P  0.0001 
vs placebo). These improvements were sustained throughout 
the 12-week study period (Table 3).
In summary, armodafinil relieves residual ES associated 
with treated OSA and improves ES-related sequelae, such as 
fatigue and memory deficits, allowing patients to re-engage 
with their normal daily lives.
Armodafinil for ES in SWD
Shift work, including night and rotating shifts, is a 
regular component of the working pattern for millions 
of individuals worldwide, including almost 22 million 
Americans.43 These individuals are at risk of SWD, a circa-
dian rhythm sleep disorder that arises from misalignment 
with the endogenous circadian sleep/wake cycle as a result 
of the artificial sleep/wake pattern imposed by shift work.44 
SWD (defined by a diagnosis of insomnia and/or ES) 
has been reported to affect 32% of night-shift workers 
and 26% of rotating-shift workers.2 Such individuals are 
at increased risk for a variety of potentially serious medi-
cal sequelae, including gastrointestinal and cardiovascular 
disease, and also may experience detrimental effects to their 
social, economic, and personal quality of life.2,8,45–47 The 
persistent ES and insomnia that are the defining symptoms 
of SWD result in elevated rates of work absenteeism and 
place affected individuals at considerably increased risk for 
accidents compared with shift workers without SWD.2
In a 12-week phase III study of 216 permanent or rotating 
night-shift workers randomized to receive armodafinil 
150 mg 30 to 60 minutes before the start of their scheduled 
work period, active treatment significantly improved sleep 
latency on the MSLT compared with placebo at the final 
study assessment (P  0.0001).41 Importantly, the wake-
fulness benefit for armodafinil was sustained throughout 
the work period (Table 3) but did not affect scheduled 
sleep.40 CGI-C ratings improved in a greater proportion of 
patients treated with armodafinil than in the placebo group 
(75% vs 59%, respectively; P = 0.001).40 Patients treated 
with armodafinil also reported a statistically significant 
reduction in the maximum level of sleepiness during the work 
period compared with those who received placebo (2.0 vs 
1.1 points on the Karolinska Sleepiness Scale; P  0.0001) Neuropsychiatric Disease and Treatment 2010:6 422
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and a statistically significant twofold reduction in sleepiness 
during the commute home (1.2 vs 0.6 points; P = 0.0027), a 
key risk period for sleepiness-related accidents.40
Armodafinil for ES in narcolepsy
Narcolepsy is an intrinsic sleep/wake disorder with a primary 
presenting symptom of  ES. Although the estimated prevalence 
of this condition is low (1% of the US population),48 there 
are variants of narcolepsy that also warrant clinical attention.49 
The cognitive impact of this disorder is considerable, with 
patients typically experiencing impaired concentration as 
well as learning and memory difficulties. ES is the hallmark 
of narcolepsy and this symptom has a significant impact on 
patients’ ability to function safely and effectively in their 
daily lives.
A phase III study has confirmed the benefit of armodafinil 
in addressing the ES component of narcolepsy.42 This 
12-week study evaluated 194 men (aged 18 to 65 years) 
with narcolepsy diagnosed according to the International 
Classification of Sleep Disorders Criteria.1 Patients received 
either armodafinil (150 mg or 250 mg daily) or placebo for 
up to 12 weeks. Daytime sleep tendency (assessed using 
the MWT) during the period 09:00 to 15:00 improved 
significantly with active treatment (+1.9 minutes for both 
armodafinil treatment groups combined) compared with 
a reduction of 1.9 minutes among those who received 
placebo (P  0.01 vs armodafinil). As reported for OSA, the 
beneficial effects of armodafinil were sustained late in the 
waking day (15:00 to 19:00), with sleep latency improve-
ments from baseline of 1.6 minutes for both armodafinil 
treatment groups combined compared with a reduction of 
1.2 minutes for those who received placebo (P  0.05 vs 
armodafinil) (Figure 3; Table 3). CGI-C assessments indi-
cated that the proportion of patients with at least minimal 
improvement in clinical condition at the final visit was sig-
nificantly higher in the armodafinil groups versus the placebo 
group (P  0.0001).42
Baseline ESS scores were high (∼17 points) but 
improved significantly compared with placebo for those 
patients treated with armodafinil (P  0.01) (Table 3). 
Patients treated with armodafinil also experienced sig-
nificant improvements in a variety of cognitive parameters 
including power of attention (as derived from improvements 
in choice reaction time and digit vigilance) (P  0.05), 
quality of episodic secondary memory (P  0.05), and 
speed of memory (P  0.05) at the final study assessment.42 
Patients also reported significant relief from the fatigue 
associated with this disorder (P = 0.0002 vs placebo at the 
final assessment).42
Safety of armodafinil
The most commonly reported adverse events with 
armodafinil were similar across the patient populations for 
all three approved indications, however, detailed analyses of 
the safety of armodafinil in patients with SWD were recently 
published (Table 4).39,42 Headache was the most commonly 
reported event and nausea, dizziness, and insomnia were 
the next most commonly reported events.39,42 Less than 
12% of active-treatment patients in any study withdrew 
from study treatment due to an emergent adverse event 
compared with 6% in the placebo group; headache was 
the adverse event most frequently associated with treatment 
withdrawal.36,37,39,42 A dose-dependent effect was noted for 
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Figure 2 Improvements in maintenance of wakefulness with armodafinil versus placebo 
among adults with residual ES during effective management of OSA.39 Panel A: early 
assessments (09:00 to 15:00). Panel B: late assessments (15:00 to 19:00).
Notes: *P  0.001 vs placebo; **P  0.05 vs placebo.
Abbreviations: ES, excessive sleepiness; MWT, maintenance of wakefulness test; 
OSA, obstructive sleep apnea; SEM, standard error of the mean.Neuropsychiatric Disease and Treatment 2010:6 424
Schwartz et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
headache and a number of the less frequently encountered 
adverse events including rash, depression, dry mouth, 
insomnia, and nausea.25
Further safety data concerning armodafinil have 
recently been reported in two open-label, 12-month studies, 
one of which recruited patients from one of the earlier 
armodafinil trials concerning ES associated with OSA, 
SWD, or narcolepsy, while patients in the other study were 
new to treatment.50,51 These studies enrolled a total of 1071 
patients and confirmed that headache is the most prevalent 
adverse event experienced when taking armodafinil (reported 
by 25% and 17% of armodafinil-treated patients in the two 
trials).50,51 Nasopharyngitis and insomnia were experienced 
by 17% and 14% of armodafinil-treated patients, respec-
tively.50 No clinically meaningful changes from baseline in 
laboratory variables or clinical examination findings were 
reported.51
Serious rash and multi-organ hypersensitivity reactions 
have been reported in association with the use of modafinil. 
No serious skin rashes or hypersensitivity reactions have 
been reported in clinical trials of armodafinil.25 However, 
because armodafinil is the R-isomer of modafinil, the risk 
of serious rash/hypersensitivity reaction with armodafinil 
remains possible. Similarly, psychiatric adverse experi-
ences have been reported in patients treated with modafinil. 
The incidence and type of psychiatric symptoms associated 
with armodafinil are expected to be similar to those for 
modafinil.25
Abuse potential
Armodafinil is classified as a schedule IV medication, as it has 
a lower potential for abuse compared with schedule II agents, 
such as methylphenidate and amphetamines, or schedule III 
agents such as sodium oxybate. A recent study32 reported that 
modafinil increased dopamine levels in the nucleus accum-
bens region of the brain – such increases are associated with 
the potential for abuse – and for this reason modafinil and 
armodafinil should be used with caution in patients with a 
history or at risk of drug abuse.
Therapeutic implications 
and future developments
The personal health and public safety implications of ES 
and its associated impairments have been under-recognized 
and under-treated to date. ES-associated detriments in 
wakefulness and alertness are linked with an increased risk 
for occupational and automobile accidents.2–5
There is a need to identify and treat ES to potentially 
improve the safety and well-being of patients and the wider com-
munity. Treatment of ES also has the potential to improve work 
productivity and to enhance patients’ quality of life and ability to 
engage with their daily lives. Patients with sleep/wake disorders 
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Figure 3 Improvements in MWT with armodafinil versus placebo among adults with narcolepsy. Reproduced with permission from Harsh JR, Haydak R, Rosenberg R, et al. 
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may not always be able to fully comprehend the severity or 
impact of this debilitating and potentially dangerous symptom. 
It is also possible that a lack of awareness of the availability of 
interventions for ES may also contribute to under-reporting of 
this symptom. Physician vigilance for ES as a core component 
of the clinical profile of patients with sleep/wake disorders is a 
fundamental aspect of its identification and treatment. Clinical 
recognition of ES should extend to patients at risk for sleep/wake 
disorders, including those with cardiac disease, which is often 
comorbid with OSA, as well as those presenting with general-
ized somatic symptoms for whom a differential diagnosis from 
a mood disorder should be sought.
Armodafinil has been shown to improve wakefulness 
throughout the day in patients with the sleep/wake disorders 
OSA and narcolepsy, and throughout the working period/shift 
in patients with SWD. In addition, a randomized, placebo-
controlled phase III study in 427 subjects traveling between 
the USA and France who had previously experienced jet lag 
demonstrated that armodafinil 150 mg significantly improved 
wakefulness compared with placebo, as measured using 
the MSLT (+11.7 minutes vs +4.8 minutes, respectively; 
P  0.0001).52 A number of studies are ongoing that may 
better define and expand the clinical utility of armodafinil.
Effective and well-tolerated pharmacotherapeutic 
options are now available for the treatment of ES associated 
with sleep/wake disorders. It is important that physicians 
include the recognition and treatment of ES as a part of their 
management program.
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